EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Perfluorohexyloctane eye drops in treating dry eye disease associated with meibomian gland dysfunction: a post hoc analysis by baseline severity

Ziyu Liu, Lixiao Ma, Yunqiu Li, Lei Tian, Ying Jie

International Ophthalmology · 2026

DOI: 10.1007/s10792-026-04007-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Ophthalmology, 2026. Verfasst von Ziyu Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Tongren Hospital, Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Capital Medical University; Beijing Ophthalmology and Visua…. Hauptthemen laut MEDLINE: Fluorocarbons, Dry Eye Syndromes, Meibomian Gland Dysfunction, Meibomian Glands. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This post hoc analysis aimed to explore the effect of perfluorohexyloctane on dry eye disease (DED) associated with meibomian gland dysfunction (MGD) by baseline disease severity. METHODS: Data from a randomized phase 3 trial (NCT05515471) were divided based on the baseline severity of DED signs (total corneal fluorescein staining [tCFS] score: < 6 or ≥ 6; tear film breakup time: < 3 or ≥ 3; MGD score: < 7 or ≥ 7) or symptoms (eye dryness scores [EDS]: < 70 or ≥ 70; ocular surface disease index score: < 60 or ≥ 60). The main outcomes of interest included response rates at day 57 of tCFS score, EDS, and tCFS and EDS, safety, and tolerability. RESULTS: Participants treated with perfluorohexyloctane had greater odds of achieving EDS (odds ratio [OR]: 2.25; 95% confidence interval [CI]: 1.34, 3.80), tCFS (OR: 2.21; 95% CI: 1.38, 3.55), and tCFS and EDS (OR: 2.56; 95% CI: 1.62, 4.04) responses than those treated with 0.6% sodium chloride in the overall population. No significant treatment interaction effect was observed by any DED signs or symptoms except for a significant effect of baseline tCFS score on EDS response, with a relatively large effect in participants with tCFS ≥ 6 versus tCFS < 6 (propensity score-weighted OR: 4.35 versus 1.26; Pinteraction = 0.0317). The safety and tolerability profiles of perfluorohexyloctane stratified by baseline disease severity were generally consistent. CONCLUSION: Perfluorohexyloctane was well tolerated and improved the signs and symptoms of DED associated with MGD in patients with different baseline disease severity compared to saline control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluorocarbonsDry Eye SyndromesMeibomian Gland DysfunctionMeibomian GlandsHumansFemaleMaleOphthalmic SolutionsSeverity of Illness IndexMiddle AgedDouble-Blind MethodTreatment OutcomeTearsFollow-Up StudiesAdult

Stichwörter der Autor:innen

Disease severityMeibomian gland dysfunctionPerfluorohexyloctanePost hoc analysisTreatment response

Substanzen

FluorocarbonsOphthalmic Solutionsperfluorohexyloctane

Autor:innen und Institutionen

  • Beijing Tongren Hospital, Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Capital Medical University; Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing, China.
  • Department of Corneal Diseases, Hebei Eye Hospital, Xingtai, China.
  • Jinan Mingshui Eye Hospital, Jinan, China.
  • Beijing Tongren Hospital, Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Capital Medical University; Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing, China. tianlei0131@163.com.
  • Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Bei-Hang University and Capital Medical University, Beijing, China. tianlei0131@163.com.
  • Beijing Tongren Hospital, Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Capital Medical University; Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing, China. jie_yingcn@aliyun.com.

Förderung

  • Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes

Zitieren

APA

Liu, Z., Ma, L., Li, Y., Tian, L., & Jie, Y. (2026). Perfluorohexyloctane eye drops in treating dry eye disease associated with meibomian gland dysfunction: a post hoc analysis by baseline severity. International Ophthalmology. https://doi.org/10.1007/s10792-026-04007-9

Vancouver

Liu Z, Ma L, Li Y, Tian L, Jie Y. Perfluorohexyloctane eye drops in treating dry eye disease associated with meibomian gland dysfunction: a post hoc analysis by baseline severity. International Ophthalmology. 2026. doi:10.1007/s10792-026-04007-9

BibTeX
@article{Liu2026,
  author = {Liu, Ziyu and Ma, Lixiao and Li, Yunqiu and Tian, Lei and Jie, Ying},
  title = {Perfluorohexyloctane eye drops in treating dry eye disease associated with meibomian gland dysfunction: a post hoc analysis by baseline severity},
  journal = {International Ophthalmology},
  year = {2026},
  doi = {10.1007/s10792-026-04007-9}
}
Kostenlos starten →